



## Joint Symposium 4

EANM-ENETS Joint Symposium – Oncology and Theranostics Committee

Monday, October 19, 15:00–16:30

### Session Title

**PRRT and Systemic Therapy Options for NET**

### Chairpersons

**Valentina Ambrosini** (Bologna, Italy)

**Andreas Kjaer** (Copenhagen, Denmark)

### Programme

15:00–15:20 **Marianne Pavel** (Erlangen, Germany): How to Sequence Systemic Therapy in NET

15:20–15:45 **Arthur Braat** (Utrecht, Netherlands): PRRT: Patient Selection and Toxicities

15:45–16:10 **Christophe Deroose** (Leuven, Belgium): Response Assessment to PRRT

16:10–16:30 **Damian Wild** (Basel, Switzerland): Antagonist-Based Theranostics

### Educational Objectives

1. Provide an overview of systemic therapy options for NET and of the interplay and sequencing options with approved PRRT regimens.
2. Assist in patient selection strategies for PRRT in comparison with other approved treatment regimens.
3. Update on treatment response assessment criteria and on clinical experience on antagonist-based theranostics for NET.

### Summary

PRRT has become a routine treatment option for patients with NET, and this session focuses on key aspects of its clinical integration. It addresses patient selection strategies and sequencing options in relation to other approved systemic therapies, alongside an overview of current approaches for assessing treatment response to PRRT. The session also presents preliminary evidence on the utility and advantages of antagonist-based theranostic pairs as emerging options in NET management.

### Key Words

NET; PRRT; Systemic Treatment; Sequencing; Response Assessment; Antagonist Theranostics